BOULDER, Colo., Dec. 7, 2016 /PRNewswire/ -- Muse bio, a privately-held company leading the development of next-generation genome engineering technologies, today announced that Dr. Kevin Ness has been appointed Chief Executive Officer and member of the Board of Directors.
Kevin succeeds Muse bio's founding CEO Ryan Gill, who becomes the company's Chief Science Officer as well as remains Slade Professor, Chemical and Biological Engineering and Executive Director of the BioDesign Center at the RAS Energy Institute at the University of Colorado, Boulder.
"Kevin brings incredible experience to drive the commercialization of Muse bio's ForgeCraft™ technology," said Ryan Gill. "I am looking forward to working with Kevin to make Muse bio a tremendous success. The Company will benefit from his innovative approach to developing and commercializing novel tools in support of the biotechnology industry."
Kevin has spent his career transforming early stage ideas into successful ventures. Prior to joining Muse bio, Kevin was co-founder, Chief Technology Officer and Chief Operating Officer of 10X Genomics®. Previously, he co-founded and was Vice President of Product Development at QuantaLife®, acquired by Bio-RAD® in 2011. He and his teams developed and commercialized products such as droplet digital PCR (ddPCR™), Linked-Read sequencing, and high-throughput, single cell gene expression measurement solutions. Kevin brings the capabilities and knowledge to not only commercialize successful products but also to build valuable enterprises.
"My sincere compliments go to Ryan and the Muse bio team for developing their revolutionary ForgeCraft technology which will significantly improve the efficiency and precision of genome engineering, bringing the capabilities of genome writing to parity with genome reading," said Kevin Ness. "I am looking forward to joining Muse bio to drive ForgeCraft to commercial success."
Muse bio is enabling a new era of genome engineering that will transform our understanding of biology. Muse bio delivers power to researchers and production scientists in the field of genome engineering and synthetic biology through the combination of a powerful computer-aided forward design software package, a proprietary benchtop biofoundry and associated reagents. Its next-generation, CRISPR-based ForgeCraft technology dramatically accelerates genome engineering. For more information, please visit www.musebio.com.
SOURCE Muse bio